Tesamorelin 20mg: What Researchers Need to Know in 2026

Tesamorelin holds a distinction that almost no other research peptide can claim: it has completed Phase III clinical trials, received FDA approval, and been studied in randomized controlled trials involving hundreds of human subjects. Originally developed under the brand name Egrifta for HIV-associated lipodystrophy, tesamorelin’s research portfolio now extends into liver disease, metabolic health, and aging-related body composition — making it one of the most rigorously studied GHRH analogs available to researchers today.

What Is Tesamorelin?

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) — the endogenous hypothalamic peptide that triggers pulsatile GH secretion from the anterior pituitary. Unlike direct GH secretagogues (GHRPs), tesamorelin works upstream — it signals the pituitary to produce and release GH in its natural pulsatile pattern, preserving the physiological rhythm of GH secretion rather than forcing a pharmacological spike.

The result is a downstream elevation of insulin-like growth factor-1 (IGF-1), which mediates tesamorelin’s primary studied effect: targeted reduction of visceral adipose tissue (VAT) — the metabolically active fat stored deep in the abdominal cavity around the organs. VAT is associated with insulin resistance, cardiovascular risk, and systemic inflammation; it responds to IGF-1-mediated lipolysis in ways that subcutaneous fat does not.

Research Overview

Phase III Visceral Fat Trials: Two pivotal 26-week randomized controlled trials established tesamorelin’s primary efficacy. Subjects receiving daily subcutaneous tesamorelin showed approximately 18% reduction in visceral adipose tissue (VAT) vs. placebo (P < 0.001), with additional improvements in waist circumference, trunk fat, and belly image distress. A 2026 meta-analysis (ScienceDirect) pooling RCT data confirmed a mean VAT reduction of 27.71 cm² (95% CI: −38.37 to −17.06; P < 0.001).

Liver Fat and NAFLD: A 12-month clinical trial in HIV-positive patients with non-alcoholic fatty liver disease found tesamorelin reduced hepatic fat fraction by 37% (P=0.016). Steatosis resolution was achieved in 35% of the tesamorelin group versus 4% on placebo (P=0.0069). Mechanistic hepatic work is documented in (PMC7455119).

INSTI-Treated Patients (2023): A 2023 study (PMC10678288) confirmed continued VAT and liver fat reduction in metabolically at-risk HIV patients receiving INSTI therapy.

Metabolic Improvements: Research published in AIDS (PubMed 22495074) demonstrated that VAT reduction with tesamorelin correlates with improved triglycerides and adiponectin — key metabolic and cardiovascular risk markers.

Community Discussion: Active researcher discussion on tesamorelin protocols is available at the r/Peptides subreddit.

Potential Benefits Studied

• Visceral fat reduction — 18–27 cm² VAT reduction confirmed in multiple RCTs
• Liver fat reduction — 37% reduction in hepatic fat fraction; 35% steatosis resolution vs 4% placebo
• Waist circumference improvement — clinically significant abdominal girth reduction
• IGF-1 elevation — upstream GH stimulation producing sustained downstream IGF-1
• Metabolic profile improvement — favorable triglyceride and adiponectin changes
• Preserved pulsatile GH pattern — physiological GH release maintained
• Well-tolerated long-term — serious adverse events in <4% of subjects across 26-week trials

Dosage & Administration

The FDA-approved and Phase III-validated dose for tesamorelin is 2 mg once daily via subcutaneous injection. The 20mg vial provides ten research doses at standard concentration. Reconstitute with 2 mL bacteriostatic water (10 mg/mL); a 2 mg dose = 0.2 mL drawn into an insulin syringe.

Evening or pre-sleep injection timing aligns with the natural overnight GH secretion window. Unlike GHRPs, tesamorelin does not cause pituitary desensitization — clinical trials ran continuously for up to 52 weeks with maintained efficacy. Importantly, visceral fat reduction does not persist after discontinuation; effects reverse within weeks of stopping, which is relevant for protocol design.

Where to Find It

Tesamorelin 20mg is available for research use at combatresearch.is.

Conclusion

Tesamorelin’s research profile is exceptional in the peptide space. Few compounds can point to double-blind, placebo-controlled Phase III trials, FDA approval, and an expanding literature base covering visceral fat, liver health, and metabolic markers. For researchers studying body composition, fatty liver disease, or GH-axis optimization, tesamorelin represents the gold standard of evidence-backed peptide research — and one of the most compelling tools available in 2026.

Disclaimer: This article is for educational and research purposes only. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy. Nothing in this article constitutes medical advice. Consult a qualified healthcare professional before initiating any research protocol.